In the latest results from the 457-patient B-Clear study, published in the New England Journal of Medicine, bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis ...

GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker this morning. The fast ...

In a boost for the FTSE 100 pharma giant and boss Emma Walmsley, Bepirovirsen is likely to reach the market sooner. The Food and Drug Administration (FDA) moved the treatment onto the expedited ...